Free tool
FAERS Monitor: Vyepti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761119 or its brand name (Vyepti, Eptinezumab-Jjmr). Reports on generic versions are filed under their own applications.
Reports
9,754
Serious
2,514
26% of reports
Hospitalization
772
Death reported
68
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,135
- migraine1,565
- headache1,024
- therapeutic response shortened602
- nausea575
- fatigue526
- throat irritation384
- drug effect less than expected383
- dizziness382
- pruritus343
- nasal congestion275
- dyspnoea229
- hypersensitivity221
- vomiting213
- inappropriate schedule of product administration205
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 156 |
| 2021 | 750 |
| 2022 | 1,262 |
| 2023 | 1,668 |
| 2024 | 2,246 |
| 2025 | 2,064 |
| 2026 | 1,604 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,405 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug effect less than expectedSignal | 383 | 57.2 | 51.8 | 20,557 |
| therapeutic response shortenedSignal | 602 | 39.8 | 36.9 | 22,383 |
| migraineSignal | 1,565 | 35.9 | 34.3 | 52,467 |
| throat irritationSignal | 384 | 18.6 | 16.9 | 6,339 |
| nasal congestionSignal | 275 | 10.1 | 9.0 | 2,251 |
| headacheSignal | 1,024 | 3.5 | 3.3 | 1,904 |
| drug ineffectiveSignal | 2,135 | 3.5 | 3.4 | 4,052 |
| hypersensitivitySignal | 221 | 2.6 | 2.3 | 212 |
| inappropriate schedule of product administrationSignal | 205 | 2.5 | 2.1 | 177 |
| pruritus | 343 | 1.9 | 1.7 | 154 |
| dizziness | 382 | 1.7 | 1.5 | 100 |
| nausea | 575 | 1.6 | 1.4 | 122 |
| fatigue | 526 | 1.5 | 1.3 | 78 |
| vomiting | 213 | 1.0 | 0.9 | 0 |
| dyspnoea | 229 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.